顾晓琳¹;郑高锋²;韩晓雁²;蔡真²

• 1:浙江省舟山市普陀人民医院血液科，浙江 舟山 316100
• 2:浙江大学医学院附属第一医院骨髓移植中心，浙江 杭州 310003

摘要(Abstract)：

关键词(KeyWords)： 多发性骨髓瘤;DECP 样方案;复发/难治

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目(81872322)

作者(Authors): 顾晓琳¹;郑高锋²;韩晓雁²;蔡真²

DOI: 10.13267/j.cnki.syzlzz.2022.027

参考文献(References)：

• [1] Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma:novel agents, antibodies, immunotherapies and beyond[J]. Leukemia, 2018, 32(2):252-262.
  [2] 黄菊,韩艳霞,王宙政,等.多发性骨髓瘤髓外复发患者二例[J].实用肿瘤杂志, 2020, 35(5):469.
  [3] Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma:a single-arm, phase 2 trial[J]. Lancet Haematol, 2019, 6(10):e521-e529.
  [4] 肖希斌,李萍,梁爱斌,等.《嵌合抗原受体T细胞疗法的免疫相关不良事件管理:ASCO指南》解读[J].实用肿瘤杂志, 2022, 37(1):1-7.
  [5] Dadacaridou M, Papanicolaou X, Maltesas D, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients[J]. J BUON, 2007, 12(1):41.
  [6] Yuen H, Low M, Fedele P, et al. DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma[J]. Leuk Lymphoma, 2018, 59(12):2842.
  [7] Park S, Lee SJ, Jung CW, et al. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents[J]. Ann Hematol, 2014, 93(1):99.
  [8] Ronchetti AM, Isnard F, Buffet M, et al. Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents[J]. Leuk Lymphoma, 2013, 54(5):1117-1119.
  [9] Lee CK, Barlogie B, Munshi N, et al. DTPACE:an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma[J]. J Clin Oncol, 2003, 21(14):2732-2739.
  [10] Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma:early results of total therapy 3[J]. Br J Haematol, 2007, 138(2):176-185.
  [11] Goldsmith S, Fiala MA, Wang BB, et al. D.C.E.P. in patients with quad-or penta-refractory multiple myeloma[J]. Blood, 2018, 132(1_suppl):2021.
  [12] Goldsmith SR, Fiala MA, Wang B, et al. DCEP and bendamustine/prednisone as salvage therapy for quad-and penta-refractory multiple myeloma[J]. Ann Hematol, 2020, 99(5):1041.
  [13] Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(12):1685.